OXIDATIVE STATUS AND ORAL-CONTRACEPTIVE - ITS RELEVANCE TO PLATELET ABNORMALITIES AND CARDIOVASCULAR RISK

被引:21
|
作者
CIAVATTI, M
RENAUD, S
机构
[1] INSERM Unit 63, 69675 Bron Cedex, 22 avenue Doyen Lepine
关键词
FREE RADICAL; LIPID PEROXIDATION; HORMONAL CONTRACEPTIVE; THROMBOSIS; PLATELETS; VITAMIN-E; VITAMIN-C; BETA-CAROTENE; GLUTATHIONE;
D O I
10.1016/0891-5849(91)90039-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oral contraceptive (OC) use is a risk for thrombogenic events. This paper reviews effects of OC on oxidative status, coagulation, and platelet activity. Complicating effects of cardiovascular risk factors such as smoking, diabetes, hyperlipidemia, and hypertension, are discussed. From these data we conclude that: 1. OC use modifies slightly but significantly the oxidative status in women and in animals by decreasing in plasma and blood cells the antioxidant defenses (vitamins and enzymes). 2. The changes in the oxidative status are related to an increase in plasma lipid peroxides apparently responsible for the hyperaggregability and possibly the imbalance in clotting factors associated with the OC-induced prethrombotic state. 3. These effects of OC appear to be increased by a high intake of polyunsaturated fat and counteracted by supplements of vitamin E. 4. The risk factors acting synergistically with OC, have all been shown to increase platelet reactivity. In addition, smoking, diabetes, and, to some extent, dyslipidemia are associated with an increased level of lipid peroxides and concomitant changes in the antioxidant defenses that can be additive to those induced by OC. Thus, free radicals and lipid peroxidation could be the underlying mechanism in the predisposition to thrombosis induced by most risk factors in OC users. 5. Results of epidemiologic and experimental studies in this field will be concordant only when diet and natural antioxidants will be systematically taken into consideration.
引用
收藏
页码:325 / 338
页数:14
相关论文
共 50 条
  • [1] CARDIOVASCULAR RISK STATUS AND ORAL-CONTRACEPTIVE USE - UNITED-STATES, 1976-1980
    RUSSELLBRIEFEL, R
    EZZATI, TM
    FULWOOD, R
    PERLMAN, JA
    MURPHY, RS
    [J]. PREVENTIVE MEDICINE, 1986, 15 (04) : 352 - 362
  • [2] CARDIOVASCULAR HAZARDS OF ORAL-CONTRACEPTIVE USE
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 237 (23): : 2530 - 2531
  • [3] ON ORAL-CONTRACEPTIVE SAFETY - CARDIOVASCULAR PROBLEMS
    EDGREN, RA
    [J]. INTERNATIONAL JOURNAL OF FERTILITY, 1981, 26 (04) : 241 - 244
  • [4] LIVER AND GUT ABNORMALITIES - ORAL-CONTRACEPTIVE USERS
    CAMILLERI, M
    SCHAFLER, K
    CHADWICK, VS
    HODGSON, HJF
    WEINBREN, HK
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1981, 11 (02) : 6 - 6
  • [5] ORAL-CONTRACEPTIVE AGENTS - CURRENT STATUS
    MASTERSON, BJ
    [J]. AMERICAN JOURNAL OF SURGERY, 1988, 155 (04): : 619 - 627
  • [6] ORAL-CONTRACEPTIVE USE, SMOKING, AND CARDIOVASCULAR REACTIVITY
    DAVIS, MC
    MATTHEWS, KA
    [J]. PSYCHOPHYSIOLOGY, 1988, 25 (04) : 441 - 442
  • [7] ORAL-CONTRACEPTIVE USE AND THE RISK OF CANCER
    WINGO, PA
    [J]. CONTRACEPTION FERTILITE SEXUALITE, 1989, 17 (02): : 125 - 132
  • [8] ORAL-CONTRACEPTIVE USE AND THE RISK OF MALARIA
    MATI, JKG
    SINEI, SK
    MULANDI, TN
    NDAVI, PM
    MBUGUA, S
    MAILU, CK
    MUNGAI, JW
    [J]. EAST AFRICAN MEDICAL JOURNAL, 1986, 63 (06) : 382 - 388
  • [9] CHROMOSOME-ABNORMALITIES IN ORAL-CONTRACEPTIVE BREAKTHROUGH PREGNANCIES
    HARLAP, S
    SHIONO, P
    PELLEGRIN, F
    GOLBUS, M
    BACHMAN, R
    MANN, J
    SCHMIDT, L
    LEWIS, JP
    [J]. LANCET, 1979, 1 (8130): : 1343 - 1343
  • [10] ORAL-CONTRACEPTIVE USE AND RISK OF STROKE
    XUEREB, M
    PULLICINO, P
    [J]. STROKE, 1988, 19 (07) : 922 - 923